TrialSignal
Clinical trial intelligence report
An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 17, 2026
NCT ID
NCT01285583
Status
COMPLETED
Phase
Phase 2/3
Sponsor
Hoffmann-La Roche
Executive brief
Investment-Ready Snapshot
TRO19622 is being evaluated as an add-on therapy to riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS), a market with significant unmet medical need and limited treatment options. The completion of this safety extension study suggests a commitment from Hoffmann-La Roche to further explore the therapeutic potential of TRO19622 in ALS, which may enhance its competitive positioning against existing therapies. The ALS market is characterized by high demand for innovative treatments, and successful outcomes could lead to substantial market share. However, the competitive landscape includes established therapies like edaravone and ongoing research into novel agents, necessitating thorough diligence on clinical efficacy and safety profiles.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01285583
Indication
Amyotrophic Lateral Sclerosis
Modality
small molecule
Target
TRO19622 (Olesoxime) is a small molecule that targets mitochondrial function and neuroprotection, potentially modulating cellular stress responses in motor neurons.
Intervention
TRO19622
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.